Compounded Tirzepatide vs Zepbound/Mounjaro: The Complete Comparison
Tirzepatide background: a more complex molecule than semaglutide
Before comparing branded and compounded versions, it is useful to understand what tirzepatide is:
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single 39-amino-acid peptide that activates both the GLP-1 receptor and the GIP receptor. It is more complex than semaglutide (a single GLP-1 agonist).
The complexity matters for compounding: tirzepatide synthesis requires advanced pharmaceutical chemistry, and quality control for a dual-agonist peptide is technically more demanding than for a single-agonist. This is relevant when assessing compounding pharmacy capability.
What compounded tirzepatide is
Compounded tirzepatide is a preparation of the same active ingredient (tirzepatide) as Zepbound and Mounjaro, produced by a §503A or §503B compounding pharmacy. It was legally permitted during the FDA-declared tirzepatide shortage (2022–March 2025).
Like compounded semaglutide, it:
- Contains the same active molecule
- Is not FDA-approved (the compounded preparation itself has not been reviewed by the FDA)
- Is not covered by insurance
- Varies in quality across pharmacies
Price comparison
| Branded (Zepbound) | Compounded tirzepatide | |
|---|---|---|
| List price | ~$1,060/month | $299–$449/month |
| LillyDirect programme (income-qualified) | ~$550/month | N/A |
| Commercial insurance (prior auth) | $25–75/month copay | Not covered |
| Cash pay without assistance | ~$1,060/month | $299–$449/month |
Compounded tirzepatide is more expensive than compounded semaglutide — reflecting the more complex manufacturing requirements. But it is still approximately 55–70% cheaper than branded Zepbound at cash pay. For branded pricing and savings programmes, see the Zepbound cost guide.
Quality considerations specific to tirzepatide
The tirzepatide compounding market had a narrower quality track record than the semaglutide compounding market because:
- Tirzepatide's molecular complexity makes synthesis errors more likely and harder to detect without sophisticated analytical testing
- The tirzepatide shortage designation was shorter — less time for compounding pharmacy infrastructure to mature
- Fewer established API (active pharmaceutical ingredient) suppliers exist for tirzepatide API than for semaglutide API, creating supply chain quality variance
The FDA issued specific warnings about compounded tirzepatide preparations, noting that some pharmacies were using tirzepatide salts (acetate, hydrochloride) rather than tirzepatide free base. The FDA stated that salt forms of tirzepatide have not been shown to be bioequivalent to the base form used in Zepbound and Mounjaro.
Critically: Unlike semaglutide, where salt-vs-base was a quality distinction that emerged over time, for tirzepatide the FDA issued its warning about salt forms relatively early in the compounding market's existence. Any pharmacy that continued to use salt forms after this warning should be avoided.
The shortage timeline for tirzepatide
- 2022–2023: Tirzepatide shortage declared (Mounjaro demand far exceeded Eli Lilly manufacturing capacity)
- 2023: Zepbound approved; shortage applies to both Mounjaro and Zepbound
- March 2025: FDA declared the tirzepatide shortage resolved — Eli Lilly certified national supply is adequate
- Post-March 2025: §503A compounding of tirzepatide became legally impermissible for most patients
The tirzepatide shortage resolution followed the semaglutide resolution by approximately a month. The same legal framework applies: §503A pharmacies can only compound tirzepatide for patients with documented specific needs that the branded product cannot meet. See the 503A vs 503B compounding explainer for how these two pharmacy categories differ.
What a legitimate post-shortage compounding situation looks like
After the shortage ended, the only legally permissible bases for §503A compounding of tirzepatide include:
- Documented allergy to a branded product excipient — if a patient has confirmed allergy to a non-active ingredient in Zepbound or Mounjaro that cannot be accommodated by the branded product
- Specific strength not commercially available — the branded pens come in specific doses; a physician-documented need for an intermediate dose could potentially qualify
- 503B outsourcing facility provisions — §503B facilities had a different compliance timeline and different regulatory requirements
Patients currently receiving compounded tirzepatide should understand the regulatory basis on which their compounding pharmacy is operating.
The Eli Lilly lawsuit against compounders
Eli Lilly has been more aggressive than Novo Nordisk in pursuing legal action against compounding pharmacies. Multiple compounders received cease-and-desist letters from Eli Lilly in 2024-2025, with some cases proceeding to litigation.
The legal arguments in these cases involve:
- FDA regulations on compounding exclusivity
- Patent protection for the tirzepatide molecule and formulation
- Trademark and trade dress claims
The outcome of these cases will affect the legal landscape for tirzepatide compounding. Patients should be aware that their compounding pharmacy's ability to continue operating may be subject to this litigation.
Comparing specific quality indicators
What to ask your tirzepatide compounding pharmacy
- Is the API tirzepatide free base or a salt form? The only acceptable answer is free base.
- Do you have a COA (Certificate of Analysis) for each batch? Should show: identity test, potency, sterility, endotoxin levels.
- What is the PCAB accreditation status? PCAB accreditation for sterile preparations is a positive quality signal.
- What is the concentration and formulation? Should be clearly stated: typically 5 mg/mL, with bacteriostatic water and pH buffer.
- Has the pharmacy received any FDA 483 observations or warning letters? Searchable via FDA's database.
Head-to-head: should I choose compounded tirzepatide or compounded semaglutide?
If a patient cannot afford branded versions of either drug and is choosing between compounded tirzepatide and compounded semaglutide, the relevant considerations are:
Weight loss: Tirzepatide produces approximately 47% more relative weight loss than semaglutide at equivalent therapeutic doses (SURMOUNT-5 head-to-head trial). For patients prioritising maximum weight loss, this is a meaningful difference.
Cost: Compounded semaglutide is cheaper (typically $150–$300/month vs $299–$449/month for tirzepatide).
Quality market maturity: Compounded semaglutide has a more established quality track record in the compounding market. Tirzepatide compounders are newer.
Regulatory risk: Both have similar regulatory risk — neither has a solid legal basis for most patients post-shortage. Tirzepatide has additional Eli Lilly litigation risk.
Our compounded vs brand semaglutide article covers the semaglutide side of this comparison in more detail.
Summary
Compounded tirzepatide costs 55–70% less than branded Zepbound at cash pay while delivering the same active molecule. The quality considerations are real — tirzepatide's molecular complexity makes compounding more technically demanding than semaglutide, and the salt-vs-base issue is a specific risk to verify. The legal basis for compounding changed after the FDA resolved the tirzepatide shortage in March 2025. Eli Lilly's litigation against compounders adds a supply stability risk not present for semaglutide compounders. Patients choosing compounded tirzepatide should prioritise PCAB-accredited pharmacies with documented batch COAs and confirmed use of tirzepatide free base. For a broader view of GLP-1 long-term safety data, see our regulatory overview.